# Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

> **NCT00324506** · PHASE2 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 43 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Mycophenolate Mofetil (CellCept)

## Key facts

- **NCT ID:** NCT00324506
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2013-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00324506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00324506, "Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00324506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*